Emerging topics in anaemia and cancer

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Aapro, M ^a  

^a CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

Chemotherapy induced anaemia; Disease progression; Erythropoiesis stimulating agents; Erythropoietin receptor; Hepcidin; Iron

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FERRIC GLUCONATE; FERRITIN; IRON; IRON DEXTRAN; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PLACEBO; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; TRANSFERRIN; TRASTUZUMAB; VINCRISTINE;

ANAPHYLAXIS; ANEMIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC DISEASE; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ANTAGONISM; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON STORAGE; LARGE CELL LYMPHOMA; NEOPLASM; NONHUMAN; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE; TUMOR CELL; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, INTRAVENOUS; ANEMIA, IRON-DEFICIENCY; ANTIMICROBIAL CATIONIC PEPTIDES; DISEASE PROGRESSION; EPIRUBICIN; ERYTHROCYTES; ERYTHROID PRECURSOR CELLS; HEMATINICS; HUMANS; IRON; META-ANALYSIS AS TOPIC; NEOPLASMS; QUALITY OF LIFE; RECEPTORS, ERYTHROPOIETIN;

EID: 84866767779     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds345     Document Type: Article

References (10)

1. Aapro M. Supportive care and palliative care: a time for unity in diversity. Ann Oncol 2012; 23: 1932-1934.
2. Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21(Suppl. 5): v232-v243.
3. Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47: 8-32.
4. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007; 43: 258-270.
5. Aapro M, Jelkmann W, Constantinescu SN et al. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 2012; 106: 1249-1258.
6. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23: 5960-5972.
7. Untch M, Fasching PA, Konecny GE et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/ cyclophosphamide followed by paclitaxel {+/-} darbepoetin alfa in primary breast cancer-results at the time of surgery. Ann Oncol 2011; 22: 1988-1998.
8. Untch M, von Minckwitz G, Konecny GE et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis. Ann Oncol 2011; 22: 1999-2006.
9. Aapro M, Österborg A, Gascón P et al. Prevalence and management of cancerrelated anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol first published online 9 May 2012, doi:10.1093/annonc/mds112
10. Schrijvers D, De Samblanx H, Roila F; ESMO Guidelines Working Group. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 2010; 21(Suppl. 5): v244-v247.